Note: This document contains side effect information about tralokinumab. Some dosage forms listed on this page may not apply to the brand name Adbry.
Applies to tralokinumab: subcutaneous solution.
Serious side effects of Adbry
Along with its needed effects, tralokinumab (the active ingredient contained in Adbry) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking tralokinumab:
More common
- Body aches or pain
- burning, dry, or itching eyes
- chills
- cough
- discharge, excessive tearing
- ear congestion
- fever
- headache
- loss of voice
- redness, pain, swelling of the eye, eyelid, or inner lining of eyelid
- stuffy or runny nose
- trouble breathing
- unusual tiredness or weakness
Less common
- Black, tarry stools
- chest pain
- painful or difficult urination
- sore throat
- sores, ulcers, or white spots on lips or in mouth
- swollen glands
- unusual bleeding or bruising
Incidence not known
- Chest tightness
- difficulty swallowing
- dizziness
- fast heartbeat
- hives, itching, skin rash
- large, hive-like swelling on face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs
- puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
Other side effects of Adbry
Some side effects of tralokinumab may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.
Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
More common
- Bleeding, blistering, burning, coldness, discoloration of the skin, feeling of pressure, hives, infection, inflammation, itching, lumps, numbness, pain, rash, redness, scarring, soreness, stinging, swelling, tenderness, tingling, ulceration, or warmth at the injection site
For Healthcare Professionals
Applies to tralokinumab: subcutaneous solution.
Respiratory
Very common (10% or more): Upper respiratory tract infections (included upper respiratory tract infection, viral upper respiratory tract infection, pharyngitis, nasopharyngitis, common cold; up to 30%)[Ref]
Ocular
Very common (10% or more): Conjunctivitis (included conjunctivitis, allergic conjunctivitis; up to 13.6%)
Common (1% to 10%): Allergic conjunctivitis
Uncommon (0.1% to 1%): Keratitis (including keratoconjunctivitis, atopic keratoconjunctivitis, ulcerative keratitis)
Immunologic
Common (1% to 10%): Anti-drug antibody
Uncommon (0.1% to 1%): Neutralizing antibodies
Hematologic
Common (1% to 10%): Eosinophilia (included eosinophilia, increased eosinophil count)
Dermatologic
Uncommon (0.1% to 1%): Eczema herpeticum[Ref]
Local
Very common (10% or more): Injection site reactions (included pain, swelling, erythema/redness; up to 11.1%)[Ref]
